Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer

Molecular Therapy

Volumn 15, Issue 5, 2007, Pages 1016-1023

  Freytag, Svend O ^a   Movsas, Benjamin ^a   Aref, Ibrahim ^a   Stricker, Hans ^a   Peabody, James ^a   Pegg, Jan ^a   Zhang, Yingshu ^a   Barton, Kenneth N ^a   Brown, Stephen L ^a   Lu, Mei ^a   Savera, Adnan ^a   Kim, Jae Ho ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIANDROGEN; CYTOSINE DEAMINASE; FLUCYTOSINE; GONADORELIN DERIVATIVE; VALGANCICLOVIR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DYSURIA; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERMAGNESEMIA; HYPONATREMIA; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; METABOLIC DISORDER; NEUTROPENIA; NOCTURIA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHOTOPHOBIA; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROTHROMBIN TIME; RIGOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUICIDE GENE THERAPY; SWEATING; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY FREQUENCY; URINE RETENTION; UROGENITAL TRACT DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; VISUAL DISORDER;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; HYPERGLYCEMIA; LYMPHOPENIA; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 34247218184     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.sj.6300120     Document Type: Article

References (50)

1. American Cancer Society (2005). Cancer facts and figures 2005. American Cancer Society: Atlanta.
2. D'Amico, AV, Whittington, R, Malkowicz, SB, Schultz, D, Blank, K, Broderick, GA et al. (1998). Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
3. Shipley, WU, Thames, HD, Sandler, HM, Hanks, GE, Zietman, AL, Perez, CA et al. (1999). Radiation therapy for clinically localized prostate cancer. JAMA 281: 1598-1604.
4. Kim, JH, Kim, SH, Brown, SL and Freytag, SO (1994). Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 54: 6053-6056.
5. Khil, MS, Kim, JH, Mullen, CA, Kim, SH and Freytag, SO (1995). Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res 2: 53-57.
6. Freytag, SO, Rogulski, KR, Paielli, DL, Gilbert, JD and Kim, JH (1998). A novel three-pronged approach to selectively kill cancer cells: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 9: 1323-1333.
7. Rogulski, K, Wing, M, Paielli, D, Gilbert, J, Kim, JH, Freytag, S et al. (2000). Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 11: 67-76.
8. Rogulski, KR, Freytag, SO, Zhang, K, Gilbert, JD, Paielli, DL, Kim, JH et al. (2000). In vivo antitumor activity, of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 60: 1193-1196.
9. Freytag, S, Paielli, D, Wing, M, Rogulski, K, Brown, S, Kolozsvary, A et al. (2002). Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 54: 873-885.
10. Freytag, SO, Khil, M, Stricker, H, Peabody, J, Menon, M, DePeralta-Venturina, M et al. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976.
11. Freytag, SO, Stricker, H, Pegg, J, Paielli, D, Pradhan, DG, Peabody, J et al. (2003). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly-diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497-7506.
12. Freytag, SO, Stricker, H, Peabody, J, Pegg, J, Paielli, D, Movsas, B et al. (2007). Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15: 636-642.
13. Herman, JR, Adler, HL, Aguilar-Cordova, E, Rojas-Martinez, A, Woo, S, Timme, TL et al. (1999). In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10: 1239-1249.
14. Teh, BS, Aguilar-Cordova E, Kernen, K, Chou, CC, Shaley, M, Vlachaki, MT et al. (2001). Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int J Radiat Oncol Biol Phys 51: 605-613.
15. DeWeese, TL, van der Poel, H, Li, S, Mikhak, B, Drew, R, Goermann, M et al. (2001). A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61: 7464-7472.
16. Kubo, H, Gardner, TA, Wada, Y, Koeneman, KS, Gotoh, A, Yang, L et al. (2003). Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 14: 227-241.
17. Teh, BS, Ayala, G, Aguilar, L, Mai, WY, Timme, TL, Vlachaki, MT et al. (2004). Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys 58: 1520-1529.
18. Small, EJ, Carducci, MA, Burke, JM, Rodriguez, R, Fong, L, van Ummersen, L et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
19. Barton, KN, Paielli, D, Zhang, Y, Koul, S, Brown, SL, Lu, M et al. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and the ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 13: 347-356.
20. Tollefson, AE, Scaria, A, Hermiston, TW, Ryerse, JS, Wold, LJ and Wold, WS (1996). The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 70: 2296-2306.
21. Tollefson, AE, Ryerse, JS, Scaria, A, Hermiston, TW and Wold, WS (1996). The E3-11.6 kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants. Virology 220: 152-162.
22. Doronin, K, Toth, K, Kuppuswamy, M, Ward, P, Tollefson, AE and Wold, WS (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 74: 6147-6155.
23. Doronin, K, Kuppuswamy, M, Toth, K, Tollelfson, AE, Krajcsi, P, Krougliak, V et al. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 75: 3314-3324.
24. Toth, K, Tarakanova, V, Doronin, K, Ward, P, Kuppuswamy, M, Locke, JE et al. (2003). Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 10: 193-200.
25. Pollack A, Zagars, GK, Starkschall, G, Antolak, JA, Lee, JJ, Huang, E et al. (2002). Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097-1105.
26. Pollack A, Zagars, GK, Antolak, JA, Kuban, D and Rosen, II (2002). Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54: 677-685.
27. Zelefsky, MJ, Fuks, Z, Hunt, M, Lee, HJ, Lombardi, D, Ling, CC et al. (2001). High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876-881.
28. Cox, J and Kaplan, R. for the American Society for Therapeutic Radiology and Oncology Consensus Panel. (1997). Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37: 1035-1041.
29. Buyounouski, MK, Hanlon, AL, Eisenberg, DF, Horwitz, EM, Feigenberg, SJ, Uzzo, RG et al. (2005). Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63: 1455-1462.
30. Valicenti, RK, DeSilvio, M, Hanks, GE, Porter, A, Brereton, H, Rosenthal, SA et al. (2006). Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer specific survival: An analysis of radiation therapy oncology group protocol 92-02. Int J Rad Oncol Biol Phys 66: 1064-1071.
31. Fleshner, NE, O'Sullivan, M and Fair, WR (1997). Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 158: 505-509.
32. Epstein, JI, Walsh, PC, Sauvageot, J and Carter, HB (1997). Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 158: 1886-1890.
33. Norberg, M, Egevad, L, Holmberg, L, Sparen, P, Norlen, BJ and Busch, C (1997). The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50: 562-566.
34. Svetec, D, McCabe, K, Peretsman, S, Klein, E, Levin, H, Optenberg, S et al. (1998). Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol 159: 1606-1608.
35. Eskew, LA, Bare, RL and McCullough, DL (1997). Systemstik 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157: 199-203.
36. Crook, JM, Perry, GA, Robertson, S and Esche, BA (1995). Routine prostate biopsies following radiotherapy for prostate cancer: Results for 226 patients. Urology 45: 624-632.
37. Crook, JM, Bahadur, YA, Robertson, SJ, Perry, GA and Esche, BA (1997). Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer 79: 81-89.
38. Crook, JM, Bahadur, YA, Bociek, RG, Perry, GA, Robertson, SJ and Esche, BA (1997). Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79: 328-336.
39. Crook, JM, Malone, S, Perry, G, Bahadur, Y, Robertson, S and Abdolell, M (2000). Postradiotherapy prostate biopsies: What do they really mean? results for 498 patients. Int J Radiat Oncol Biol Phys 48: 355-367.
40. Scardino, PT and Wheeler, TM (1988). Local control of prostate cancer with radiotherapy. Frequency and prognostic significance of positive results of postirradiation prostate biopsy. Natl Cancer Inst Monogr 7: 95-103.
41. Kuban, DA, el-Mahdi, AM and Schellhammer, P (1992). The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 24: 409-414.
42. Prestidge, BR, Kaplan, I, Cox, RS and Bagshaw, MA (1992). The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int J Radiat Oncol Biol Phys 24: 403-408.
43. Vaillancourt, L, Ttu, B, Fradet, Y, Dupont A, Gomez, J, Cusan, L et al. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study. Am J Surg Pathol 20: 86-93.
44. Bergelson, JM, Cunningham, JA, Drouguett, G, Kurt-Joned, EA, Krithivas, A, Hong, JS et al. (1997). Isolation of a common receptor for coxsackie B viruses and adenovirus 2 and 5. Science 275: 1320-1323.
45. Wickham, TJ, Mathias, P, Cheresh, DA and Nemerow, GR (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319.
46. Hemmi, S, Geertsen, R, Mezzacasa, A, Peter, I and Drummer, R (1998). The presence of human coxsackie and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Gene Ther 9: 2363-2373.
47. Richardson, C, Brennan, P, Powell, M, Prince, S, Chen, YH, Spiller, OB et al. (2005). Susceptibility of B lymphocytes to adennovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alpha v beta 5 integrin expression. J Gen Virol 86: 1669-1679.
48. Li, Y, Pong, RC, Bergelson, JM, Hall, MC, Sagalowsky, AI, Tseng, CP et al. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res 59: 325-330.
49. Okegawa, T, Li, Y, Pong, RC, Bergelson, JM, Zhou, J and Hsieh, JT (2000). The dual impact of coxsackie and adenovirus receptor expression in human prostate cancer gene therapy. Cancer Res 60: 5031-5036.
50. Rauen, K, Sudilovsky, D, Le J, Chew, K, Hann, B, Weinberg, V et al. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res 62: 3812-3818.